• Results
  • Key finding: COVID-19: R&D for COVID-19 has increased, yet other pan...
Key finding: COVID-19

R&D for COVID-19 has increased, yet other pandemic risks go unaddressed

Despite years of warnings that novel coronaviruses were among the pathogens most likely to cause a global health emergency, the pharmaceutical industry, as well as society at large, was ill-prepared for the COVID-19 pandemic.

Explore further

How we measure

How we measure

The Index evaluates pharmaceutical companies in areas where they have the biggest potential and responsibility to make change, such as R&D and pricing. Find out more about the analytical framework and areas of evaluation.

Get in touch

Back to top |